Home Featured Page 154

Featured

Latest

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord...

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results

atai Life Sciences to Announce Second Quarter 2022 Financial Results and...

BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada:...

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company...

Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in...

1...153154155...300 Page 154 of 300

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord...

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results

atai Life Sciences to Announce Second Quarter 2022 Financial Results and...

BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada:...

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company...

Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in...

EDITOR PICKS

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY